Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon

Trial Profile

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Apixaban (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary) ; Phenprocoumon
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms ReLoaDeD
  • Sponsors Bayer
  • Most Recent Events

    • 10 Dec 2018 Status changed from active, no longer recruiting to completed.
    • 27 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top